Genea welcomes ZEISS and Hamilton Thorne to the Global Fertility Alliance
Published: 30/06/2016 at 10:40 AM
As a founding member of the Global Fertility Alliance, Australian fertility pioneer Genea today welcomed two new members, ZEISS and Hamilton Thorne Ltd.
Established a year ago by Genea, Merck, a leading science and technology company, and Illumina Inc, a leader in developing and commercialising systems for analysis of genetic variation and function, the alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.
ZEISS, an internationally leading technology enterprise operating in the optics and optoelectronics industries, and Hamilton Thorne Ltd., a leading provider of precision laser devices and advanced image analysis systems for ART, regenerative medicine and developmental biology research markets, will join the founding members of the alliance and their quest to improve the consistency in ART laboratories worldwide.
An update on the alliance’s activities will be presented at the 2016 annual meeting of the European Society of Human Reproduction and Embryology (ESHRE in Helsinki, Finland.
Genea CEO Dr Tomas Stojanov said the addition of new member companies to the alliance was an important step in its work to enhance progress and innovation.
“We welcome the opportunity to collaborate with ZEISS and Hamilton Thorne, two experts in their fields that bring a new lens to the questions we are seeking to resolve, namely how to achieve standardisation of fertility processes within the ART laboratory to ensure more people are able to take home the healthy baby they strongly desire,” Dr Stojanov said.
ZEISS Microscopy Business Group Director Market Segment Education & Routine Peter Kraemer said they were impressed by the alliance’s progress so far and looked forward to contributing to improvements in ART practices through technology innovation.
“ZEISS has a strong heritage in the development of specialized microscopes and we are committed to using our expertise in this field to drive the standardization of ART processes and techniques further,” Mr Kraemer said.
Hamilton Thorne CEO David Wolf reiterated the importance of the alliance’s goal to drive automation and standardization in fertility laboratories worldwide to promote better outcomes for patients.
“As a pioneer in the field of developing instruments for the in vitro fertilization clinic, advancing the science of fertility treatment is in the DNA of our company,” Mr Wolf said.